Advanced donor age does not increase risk of hepatocellular carcinoma recurrence after liver transplantation: a retrospective two-centre analysis using competing risk analysis.
ECD graft
elderly graft
hepatocellular carcinoma
liver transplantation
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
revised:
15
04
2021
received:
20
01
2021
accepted:
22
04
2021
pubmed:
20
6
2021
medline:
21
10
2021
entrez:
19
6
2021
Statut:
ppublish
Résumé
The impact of donor age on the recurrence of hepatocellular carcinoma (HCC) after liver transplantation is still debated. Between 2002 and 2014, all patients transplanted for HCC in 2 European liver transplantation tertiary centres were retrospectively reviewed. Risk factors for HCC recurrence were assessed using competing risk analysis, and the impact of donor age < or ≥65 years and < or ≥80 years was specifically evaluated after propensity score matching. 728 patients transplanted with a median follow-up of 86 months were analysed. The 1-, 3- and 5-year recurrence rates were 4.9%, 10.7% and 13.9%, respectively. In multivariable analysis, recipient age (sHR: 0.96 [0.93; 0.98], P < 0.01), number of lesions (sHR: 1.05 [1.04; 1.06], P < 0.001), maximum size of the lesions (sHR: 1.37 [1.27; 1.48], P < 0.01), presence of a hepatocholangiocarcinoma (sHR: 6.47 [2.91; 14.38], P < 0.01) and microvascular invasion (sHR: 3.48 [2.42; 5.02], P < 0.01) were significantly associated with HCC recurrence. After propensity score matching, neither donor age ≥65 (P = 0.29) nor donor age ≥80 (P = 0.84) years increased the risk of HCC recurrence. In conclusion, donor age was not found to be a risk factor for HCC recurrence. Patients listed for HCC can receive a graft from an elderly donor without compromising the outcome.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1948-1958Informations de copyright
© 2021 Steunstichting ESOT. Published by John Wiley & Sons Ltd.
Références
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693.
Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol 2017; 14: 203.
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87.
Adam R, Karam V, Cailliez V, et al. 2018 annual report of the european liver transplant registry (ELTR) - 50-year evolution of liver transplantation. Transpl Int 2018; 31: 1293.
Rapport annuel médical et scientifique 2018, agence de la biomédecine.
Durand F, Renz JF, Alkofer B, et al. Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transpl 2008; 14: 1694.
Vodkin I, Kuo A. Extended criteria donors in liver transplantation. Clin Liver Dis 2017; 21: 289.
Angelico M, Cillo U, Fagiuoli S, et al. Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis 2011; 43: 155.
Vagefi PA, Dodge JL, Yao FY, et al. Potential role of the donor in hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2015; 21: 187.
Orci LA, Berney T, Majno PE, et al. Donor characteristics and risk of hepatocellular carcinoma recurrence after liver transplantation. Br J Surg 2015; 102: 1250.
Sharma P, Welch K, Hussain H, et al. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD Era. Dig Dis Sci 2012; 57: 806.
Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143: 986;quiz e14-15.
Fine JP, Gray RJ. A Proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association. 1999; 94: 496.
Mazzaferro V, Sposito C, Zhou J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology 2018; 154: 128.
Agopian VG, Harlander-Locke M, Zarrinpar A, et al. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: Analysis of 865 consecutive liver transplant recipients. J Am Coll Surg 2015; 220: 416.
Al-Ameri AAM, Wei X, Wen X, et al. Systematic review: risk prediction models for recurrence of hepatocellular carcinoma after liver transplantation. Transpl Int 2020; 33: 697.
Mehta N, Heimbach J, Harnois DM, et al. Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol. 2017; 3: 493.
Halazun KJ, Najjar M, Abdelmessih RM, et al. Recurrence after liver transplantation for hepatocellular carcinoma: A new moral to the story. Ann Surg 2017; 265: 557.
Piñero F, Marciano S, Anders M, et al. Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina. Euro J Gastroenterol Hepatol 2016; 28: 421.
Lozanovski VJ, Kerr LTB, Khajeh E, et al. Liver grafts with major extended donor criteria may expand the organ pool for patients with hepatocellular carcinoma. Journal of Clinical Medicine 2019; 8(10): 1692.
Hypothermic Oxygenated Perfusion for Extended Criteria Donors in Liver Transplantation (HOPExt). - Full Text View - ClinicalTrials.gov Available from: https://clinicaltrials.gov/ct2/show/NCT03929523. Accessed January 15, 2020.
Ghinolfi D, Marti J, De Simone P, et al. Use of octogenarian donors for liver transplantation: a survival analysis. Am J Transplant 2014; 14: 2062.
Wallace D, Walker K, Charman S, et al. Assessing the impact of suboptimal donor characteristics on mortality after liver transplantation: A time-dependent analysis comparing HCC With Non-HCC Patients. Transplantation 2019; 103: e89.
Ghinolfi D, De Simone P, Lai Q, et al. Risk analysis of ischemic-type biliary lesions after liver transplant using octogenarian donors. Liver Transpl 2016; 22: 588.
Gajate Martín L, Martín Grande A, Parise Roux D, et al. Short-term results of liver transplantation with octogenarian donors. Transplant Proc. 2018; 50: 184.
Ghinolfi D, Tincani G, Rreka E, et al. Dual aortic and portal perfusion at procurement prevents ischaemic-type biliary lesions in liver transplantation when using octogenarian donors: a retrospective cohort study. Transpl Int 2019; 32: 193.
El-Badry AM, Breitenstein S, Jochum W, et al. Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. Ann Surg 2009; 250: 691.